Progression of keratoconus and efficacy of pediatric [corrected] corneal collagen cross-linking in children and adolescents.
Nico Chatzis, Farhad Hafezi
https://pubmed.ncbi.nlm.nih.gov/23347367/Actively Recruiting
Led by Pacific Clear Vision Institute · Updated on 2024-11-12
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of the Peschke PXL-330 system for treating corneal thinning conditions such as progressive keratoconus, pellucid marginal degeneration, infectious keratitis, and risk of post-refractive corneal ectasia. This phase 1 study involves patients aged 12 to 45 years and aims to assess corneal strengthening using this novel crosslinking technique. Participants will receive epithelial-on corneal crosslinking using the PXL-330 system with pulsed, accelerated UV-A energy delivery. Two treatment groups include one with 18 mW pulsed illumination and another with 9 mW continuous illumination, each for about 10 minutes. The procedure uses riboflavin to load the cornea prior to UV-A exposure. Treatment is followed by monitoring over one year. During the year-long follow-up, patients will have repeated tests including corneal topography to measure corneal shape, visual acuity exams, intraocular pressure checks, and questionnaires about their vision function. The main outcome measured is mean keratometry in diopters at 12 months, with secondary outcomes including best-corrected visual acuity. Safety and vision changes will be closely tracked throughout.
CONDITIONS
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
B
BALAMURALI AMBATI, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pacific Clear Vision Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pulsed, accelerated CXL | Conventional CXL | Standard Dresden CXL |
|---|---|---|---|
| What it is | A pulsed‑light, higher‑intensity corneal cross‑linking protocol delivered using the PXL‑330 Platinum device and riboflavin | The conventional continuous UV‑A riboflavin cross‑linking protocol used as the active comparator | Standard epithelium‑off Dresden CXL is the widely accepted reference protocol for stopping keratoconus progression |
| Role in the study | Investigational regimen under assessment | Active comparator arm within the randomized design | Not included in the trial, provided for standard‑care context |
| Purpose | To halt progression of keratoconus using a shorter, pulsed lighting protocol | To halt keratoconus progression using the established continuous protocol | To stabilize progressive keratoconus and prevent vision loss |
| Procedure | Pulsed UV‑A light with riboflavin using the PXL‑330 device | Continuous UV‑A light with riboflavin applied per standard CXL protocol | Epithelium removed, riboflavin drop soak, then continuous UV‑A exposure per Dresden protocol |
| Clinical evidence | Efficacy under investigation; trial will measure mean keratometry and visual acuity at 12 months | Effectiveness as active comparator being assessed against investigational protocol | Established long‑term stabilization of keratoconus progression |
| Important risks | Comparable transient haze risk expected; long‑term safety under study | Transient haze and epithelial healing risks are known from established use | Well documented risks include transient haze, discomfort, and infection risk |
| Limitations | Effectiveness and durability not yet established; outcomes at 12 months only | Comparator effectiveness limited to trial context; trial not powered for long‑term outcomes | Protocol may involve longer procedure time and epithelial removal discomfort |
| Patient experience | Shorter treatment time may reduce time in clinic but impact on long‑term outcomes not yet known | Procedure well understood with predictable recovery over time | Proven procedure with established patient care pathway and follow‑up experience |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment day
Participants undergo epithelial-on corneal cross-linking with the PXL-330 Platinum device using pulsed or continuous UV-A illumination.
1 treatment visit (in-person)
Duration - 12 months
Participants are monitored for 1 year with serial measurements of corneal topography, visual acuity, intraocular pressure, and visual function.
Approximately 5 follow-up visits over 12 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Nico Chatzis, Farhad Hafezi
https://pubmed.ncbi.nlm.nih.gov/23347367/Aldo Caporossi, Cosimo Mazzotta, Stefano Baiocchi...
https://pubmed.ncbi.nlm.nih.gov/20138607/Aldo Caporossi, Stefano Baiocchi, Cosimo Mazzotta...
https://pubmed.ncbi.nlm.nih.gov/16765803/C Mazzotta, C Traversi, S Caragiuli...
https://pubmed.ncbi.nlm.nih.gov/25060847/Pacific Clear Vision Institute
Lead Sponsor